Microbot Medical's LIBERTY Adopted by Florida's First Hospital
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy MBOT?
Microbot Medical announced that Tampa General Hospital has become the first health system in Florida to adopt LIBERTY, marking a milestone following the Company's recent FDA 510(k) clearance. Microbot believes that this reflects early post-clearance momentum for LIBERTY and highlights growing institutional readiness for advanced robotic solutions in peripheral endovascular procedures.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MBOT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MBOT
Wall Street analysts forecast MBOT stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.410
Low
5.50
Averages
8.75
High
12.00
Current: 2.410
Low
5.50
Averages
8.75
High
12.00
About MBOT
Microbot Medical Inc. is a pre-commercial stage medical technology company. It has developed the single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems. It specializes in the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, it is developing a fully disposable robot for various endovascular interventional procedures. The LIBERTY Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the body’s vasculature. It eliminates the need for extensive capital equipment requiring dedicated Cath-lab rooms as well as dedicated staff. Its addressable markets for the LIBERTY Endovascular Robotic Surgical System include the peripheral interventional radiology, interventional cardiology and interventional neuroradiology markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Microbot Medical Secures FDA Clearance for LIBERTY System, Gains Endorsement
- FDA Clearance: Microbot Medical recently achieved FDA 510(k) clearance for its LIBERTY system, designed for precision in peripheral endovascular procedures, marking a significant advancement in medical technology.
- Hospital Adoption: The adoption by Tampa General Hospital is seen as a major endorsement of LIBERTY's value, with hospital leadership emphasizing the technology's potential to improve patient care and enhance physician safety, which may drive broader market acceptance.
- Market Demand: The LIBERTY system is the only FDA-cleared, single-use, remotely operated robotic solution in its category, aimed at addressing the growing demand in the U.S. market, which encompasses approximately 2.5 million procedures annually, indicating a strong market outlook.
- Strategic Partnership: Microbot plans to fully launch the LIBERTY system at the Society of Interventional Radiology conference in April 2026, and this strategic partnership is expected to enhance the company's commercial footprint and support market penetration.
See More
Microbot Medical Launches LIBERTY System in Florida
- Market Launch: Microbot Medical announced that Tampa General Hospital has become the first health system in Florida to adopt the LIBERTY® Endovascular Robotic System, marking a significant milestone post-FDA 510(k) clearance and expected to enhance the company's share in the approximately 2.5 million annual peripheral endovascular procedures market.
- Technological Innovation: The LIBERTY system is the world's first FDA-cleared single-use, remotely operated robotic system designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain on physicians, which is anticipated to significantly improve the quality of care and enhance physician safety.
- Collaborative Model: Tampa General Hospital's strong culture of innovation and clinical leadership makes it an ideal partner for LIBERTY, with plans to promote robotic technology across multiple specialties, thereby enhancing its capabilities in navigating complex anatomical structures and strengthening its market competitiveness.
- Market Expansion Plans: Microbot's sales team is making progress during the limited market release, with plans for a full market launch at the Society of Interventional Radiology (SIR) conference in April 2026, aiming to showcase the LIBERTY system and accelerate market adoption to drive future commercial growth.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their outlook on several companies, indicating a shift in market sentiment that could influence investor decisions and market trends.
- Overview of Ratings Updates: While specific upgrades, downgrades, and initiations are not detailed in the report, the overall changes in ratings may directly impact the stock prices of the companies involved, prompting investors to pay close attention to these shifts.
- Expected Market Reaction: Analyst rating adjustments typically lead to short-term market volatility, and investors should consider these changes as potential buy or sell signals to optimize their portfolios.
- Source Information Reminder: A complete view of all analyst rating changes can be found on Benzinga's analyst ratings page, providing a more comprehensive market insight to help investors make informed decisions.
See More
Credo Technology Raises Revenue Guidance Significantly
- Revenue Guidance Increase: Credo Technology expects to report revenue between $404 million and $408 million, significantly up from prior guidance of $335 million to $345 million, indicating strong market demand and business growth potential.
- Significant Year-over-Year Growth: The company anticipates over 200% year-over-year growth in the current fiscal year, reflecting its competitive position in the industry and rapid market share expansion.
- Quarterly Growth Outlook: Credo also expects mid-single-digit sequential revenue growth to round out the year, suggesting continued strong performance in the coming months, which enhances investor confidence.
- Positive Stock Reaction: In pre-market trading, Credo Technology shares jumped 17.4% to $144.87, reflecting market optimism regarding its financial outlook and potentially attracting more investor interest.
See More
Microbot Medical Attends Interventional Oncology Annual Meeting
- Market Release Timing: Microbot Medical is showcasing its LIBERTY® Endovascular Robotic System at the Interventional Oncology Annual Meeting from February 4-8, 2026, coinciding with its limited market release, aiming to accelerate commercial awareness and adoption through sharing physician experiences.
- First Commercial Exhibition: This conference marks the first commercial exhibition of the LIBERTY System, allowing the company to engage directly with interventional oncologists, which is expected to enhance product market traction and drive sales growth.
- Technological Innovation: LIBERTY is the only FDA-cleared single-use, remotely operated robotic system designed for peripheral endovascular procedures, aiming to improve precision and reduce radiation exposure, addressing the growing demand in interventional oncology.
- Future Market Plans: The company plans a full market release at the Interventional Radiology conference in April 2026, further showcasing LIBERTY's capabilities to promote widespread adoption in the interventional radiology field.
See More
Reasons for Our Lack of Concern Regarding Microbot Medical's (NASDAQ:MBOT) Cash Burn Issue
Investor Interest in Unprofitable Companies: Microbot Medical's share price has surged 142% over the past year, attracting investor attention despite its lack of profitability and cash burn concerns.
Cash Burn and Runway Analysis: The company reported a cash burn of $11 million over the last year, with a cash runway of approximately 7.3 years, indicating a manageable financial situation for shareholders.
Growth Investment and Future Considerations: Although Microbot Medical's cash burn increased by 23%, suggesting a focus on future growth, this could shorten its cash runway if spending continues to rise.
Raising Capital and Market Position: With a market capitalization of $159 million, Microbot Medical's cash burn represents a low percentage of its market value, indicating potential ease in raising additional funds through share issuance or borrowing.
See More
Microbot Medical Secures FDA Clearance for LIBERTY System, Gains Endorsement
- FDA Clearance: Microbot Medical recently achieved FDA 510(k) clearance for its LIBERTY system, designed for precision in peripheral endovascular procedures, marking a significant advancement in medical technology.
- Hospital Adoption: The adoption by Tampa General Hospital is seen as a major endorsement of LIBERTY's value, with hospital leadership emphasizing the technology's potential to improve patient care and enhance physician safety, which may drive broader market acceptance.
- Market Demand: The LIBERTY system is the only FDA-cleared, single-use, remotely operated robotic solution in its category, aimed at addressing the growing demand in the U.S. market, which encompasses approximately 2.5 million procedures annually, indicating a strong market outlook.
- Strategic Partnership: Microbot plans to fully launch the LIBERTY system at the Society of Interventional Radiology conference in April 2026, and this strategic partnership is expected to enhance the company's commercial footprint and support market penetration.
See More
Microbot Medical Launches LIBERTY System in Florida
- Market Launch: Microbot Medical announced that Tampa General Hospital has become the first health system in Florida to adopt the LIBERTY® Endovascular Robotic System, marking a significant milestone post-FDA 510(k) clearance and expected to enhance the company's share in the approximately 2.5 million annual peripheral endovascular procedures market.
- Technological Innovation: The LIBERTY system is the world's first FDA-cleared single-use, remotely operated robotic system designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain on physicians, which is anticipated to significantly improve the quality of care and enhance physician safety.
- Collaborative Model: Tampa General Hospital's strong culture of innovation and clinical leadership makes it an ideal partner for LIBERTY, with plans to promote robotic technology across multiple specialties, thereby enhancing its capabilities in navigating complex anatomical structures and strengthening its market competitiveness.
- Market Expansion Plans: Microbot's sales team is making progress during the limited market release, with plans for a full market launch at the Society of Interventional Radiology (SIR) conference in April 2026, aiming to showcase the LIBERTY system and accelerate market adoption to drive future commercial growth.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their outlook on several companies, indicating a shift in market sentiment that could influence investor decisions and market trends.
- Overview of Ratings Updates: While specific upgrades, downgrades, and initiations are not detailed in the report, the overall changes in ratings may directly impact the stock prices of the companies involved, prompting investors to pay close attention to these shifts.
- Expected Market Reaction: Analyst rating adjustments typically lead to short-term market volatility, and investors should consider these changes as potential buy or sell signals to optimize their portfolios.
- Source Information Reminder: A complete view of all analyst rating changes can be found on Benzinga's analyst ratings page, providing a more comprehensive market insight to help investors make informed decisions.
See More
Credo Technology Raises Revenue Guidance Significantly
- Revenue Guidance Increase: Credo Technology expects to report revenue between $404 million and $408 million, significantly up from prior guidance of $335 million to $345 million, indicating strong market demand and business growth potential.
- Significant Year-over-Year Growth: The company anticipates over 200% year-over-year growth in the current fiscal year, reflecting its competitive position in the industry and rapid market share expansion.
- Quarterly Growth Outlook: Credo also expects mid-single-digit sequential revenue growth to round out the year, suggesting continued strong performance in the coming months, which enhances investor confidence.
- Positive Stock Reaction: In pre-market trading, Credo Technology shares jumped 17.4% to $144.87, reflecting market optimism regarding its financial outlook and potentially attracting more investor interest.
See More
Microbot Medical Attends Interventional Oncology Annual Meeting
- Market Release Timing: Microbot Medical is showcasing its LIBERTY® Endovascular Robotic System at the Interventional Oncology Annual Meeting from February 4-8, 2026, coinciding with its limited market release, aiming to accelerate commercial awareness and adoption through sharing physician experiences.
- First Commercial Exhibition: This conference marks the first commercial exhibition of the LIBERTY System, allowing the company to engage directly with interventional oncologists, which is expected to enhance product market traction and drive sales growth.
- Technological Innovation: LIBERTY is the only FDA-cleared single-use, remotely operated robotic system designed for peripheral endovascular procedures, aiming to improve precision and reduce radiation exposure, addressing the growing demand in interventional oncology.
- Future Market Plans: The company plans a full market release at the Interventional Radiology conference in April 2026, further showcasing LIBERTY's capabilities to promote widespread adoption in the interventional radiology field.
See More
Reasons for Our Lack of Concern Regarding Microbot Medical's (NASDAQ:MBOT) Cash Burn Issue
Investor Interest in Unprofitable Companies: Microbot Medical's share price has surged 142% over the past year, attracting investor attention despite its lack of profitability and cash burn concerns.
Cash Burn and Runway Analysis: The company reported a cash burn of $11 million over the last year, with a cash runway of approximately 7.3 years, indicating a manageable financial situation for shareholders.
Growth Investment and Future Considerations: Although Microbot Medical's cash burn increased by 23%, suggesting a focus on future growth, this could shorten its cash runway if spending continues to rise.
Raising Capital and Market Position: With a market capitalization of $159 million, Microbot Medical's cash burn represents a low percentage of its market value, indicating potential ease in raising additional funds through share issuance or borrowing.
See More
